INT150417

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2005
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 20
Total Number 21
Disease Relevance 11.48
Pain Relevance 6.28

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (IRF6) nucleus (IRF6) DNA binding (IRF6)
cytoplasm (IRF6)
Anatomy Link Frequency
monocytes 5
neutrophils 4
neurons 2
alveolar macrophages 2
astrocytes 2
IRF6 (Homo sapiens)
Pain Link Frequency Relevance Heat
Morphine 412 100.00 Very High Very High Very High
dexamethasone 90 100.00 Very High Very High Very High
agonist 67 100.00 Very High Very High Very High
Inflammatory mediators 21 99.00 Very High Very High Very High
cytokine 228 98.28 Very High Very High Very High
Inflammation 383 97.88 Very High Very High Very High
metalloproteinase 7 95.88 Very High Very High Very High
Inflammatory response 61 95.76 Very High Very High Very High
aspirin 48 95.60 Very High Very High Very High
Angina 12 95.04 Very High Very High Very High
Disease Link Frequency Relevance Heat
Occupational Lung Diseases 149 99.68 Very High Very High Very High
INFLAMMATION 458 99.00 Very High Very High Very High
Infection 95 97.68 Very High Very High Very High
Asthma 411 97.64 Very High Very High Very High
Coronary Artery Disease 8 97.36 Very High Very High Very High
Disease 92 96.60 Very High Very High Very High
Cv General 3 Under Development 12 95.04 Very High Very High Very High
Rhinitis 18 94.72 High High
Alzheimer's Dementia 17 94.12 High High
Endotoxemia 3 91.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Lipopolysaccharide (LPS)-receptor (CD14) and HLA-DR expression on monocytes and beta-integrins (CD11b, 11c, 49d) on monocytes and lymphocytes were measured by flow cytometry before and after treatment with atorvastatin for 8 weeks.
Negative_regulation (measured) of Gene_expression (expression) of LPS in monocytes
1) Confidence 0.41 Published 2007 Journal Rom J Intern Med Section Abstract Doc Link 18333374 Disease Relevance 1.11 Pain Relevance 0.59
Gram-negative bacterial LPS: introduction and its discovery
Negative_regulation (discovery) of Gene_expression (introduction) of LPS
2) Confidence 0.23 Published 2006 Journal Environ Health Section Body Doc Link PMC1489932 Disease Relevance 0.73 Pain Relevance 0.05
M), in the presence and absence of LPS (10 ng/ml; 4 h).
Negative_regulation (absence) of Gene_expression (presence) of LPS
3) Confidence 0.15 Published 2008 Journal J Inflamm (Lond) Section Abstract Doc Link PMC2525633 Disease Relevance 0.22 Pain Relevance 0.34
Lipopolysaccharide (LPS)-receptor (CD14) and HLA-DR expression on monocytes and beta-integrins (CD11b, 11c, 49d) on monocytes and lymphocytes were measured by flow cytometry before and after treatment with atorvastatin for 8 weeks.
Negative_regulation (measured) of in lymphocytes Gene_expression (expression) of LPS in monocytes
4) Confidence 0.14 Published 2007 Journal Rom J Intern Med Section Abstract Doc Link 18333374 Disease Relevance 1.11 Pain Relevance 0.59
Besides, the study also has shown the association between LPS and chronic in vivo stimulation of monocytes, an association between raised plasma LPS; and an association between reduction in plasma LPS and CD4+ T-cell reconstitution with HAART [21].
Negative_regulation (reduction) of Gene_expression (reconstitution) of LPS in monocytes
5) Confidence 0.10 Published 2007 Journal AIDS Res Ther Section Body Doc Link PMC2216023 Disease Relevance 0.99 Pain Relevance 0.23
In addition, because it has been demonstrated that lesioning the PIT severely disrupts shape discrimination (Iwai and Mishkin 1969) and that many PIT neurons exhibit shape selectivity (Tanaka et al. 1991; Kobatake and Tanaka 1994; Brincat and Connor 2004), we also examined the shape selectivity of the same group of neurons using a set of geometrical shapes.
Negative_regulation (disrupts) of Gene_expression (lesioning) of PIT in neurons
6) Confidence 0.10 Published 2010 Journal Cerebral Cortex (New York, NY) Section Body Doc Link PMC2882824 Disease Relevance 0 Pain Relevance 0.06
Costimulation of neutrophils with LPS and morphine decreased the release of IL-8 significantly (24±2 ng/106 neutrophils ±SD, n?
Negative_regulation (neutrophils) of Gene_expression (Costimulation) of LPS in neutrophils associated with morphine
7) Confidence 0.10 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2808358 Disease Relevance 0 Pain Relevance 1.02
Costimulation of neutrophils with LPS and morphine decreased the release of IL-8 significantly (24±2 ng/106 neutrophils ±SD, n?
Negative_regulation (decreased) of Gene_expression (Costimulation) of LPS in neutrophils associated with morphine
8) Confidence 0.10 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2808358 Disease Relevance 0 Pain Relevance 1.08
However, their map does not include a number of other proteins that we found to decrease after LPS priming, like coagulation factor XIII and ras suppressor protein.
Negative_regulation (decrease) of Gene_expression (priming) of LPS
9) Confidence 0.10 Published 2008 Journal Proteome Sci Section Body Doc Link PMC2413206 Disease Relevance 0.15 Pain Relevance 0.08
Levels of LPS in such environments may exceed 20 ?
Spec (may) Negative_regulation (exceed) of Gene_expression (Levels) of LPS
10) Confidence 0.10 Published 2005 Journal Respir Res Section Body Doc Link PMC549028 Disease Relevance 0.42 Pain Relevance 0.26
The inhibitory effect of Prolastin (0.5 mg/ml) on LPS-stimulated TNF?
Negative_regulation (inhibitory) of Gene_expression (effect) of LPS
11) Confidence 0.10 Published 2005 Journal Respir Res Section Body Doc Link PMC549028 Disease Relevance 0 Pain Relevance 0.07
release was comparable in magnitude to that of native or polymeric AAT, whereas its inhibitory effect on LPS-induced IL-1?
Negative_regulation (inhibitory) of Gene_expression (effect) of LPS
12) Confidence 0.10 Published 2005 Journal Respir Res Section Body Doc Link PMC549028 Disease Relevance 0 Pain Relevance 0.04
Dexamethasone suppression of LTB4 was observed in all three groups: normal subjects (LPS: 102 ± 23 versus LPS and dexamethasone: 11.6 ± 7.7 pg/ml, p < 0.05); non-severe asthmatics (183 ± 122 versus 21.4 ± 22 pg/ml, p < 0.05) and severe asthmatics (230 ± 102 versus 60 ± 32 pg/ml, p < 0.01).
Negative_regulation (non) of Gene_expression (subjects) of LPS associated with occupational lung diseases and dexamethasone
13) Confidence 0.08 Published 2010 Journal Respir Res Section Body Doc Link PMC2894769 Disease Relevance 0.83 Pain Relevance 0.24
Our data on LXA4 is one of the first regarding its stimulated production by LPS, and its suppression by dexamethasone.
Negative_regulation (regarding) of Gene_expression (production) of LPS associated with dexamethasone
14) Confidence 0.08 Published 2010 Journal Respir Res Section Body Doc Link PMC2894769 Disease Relevance 1.41 Pain Relevance 0.65
These results are in line with the current observation of reduced basal and LPS-stimulated production of LXA4 from alveolar macrophages of patients with severe asthma.
Negative_regulation (reduced) of Gene_expression (production) of LPS in alveolar macrophages associated with asthma
15) Confidence 0.08 Published 2010 Journal Respir Res Section Body Doc Link PMC2894769 Disease Relevance 1.18 Pain Relevance 0
Dexamethasone suppression of LTB4 was observed in all three groups: normal subjects (LPS: 102 ± 23 versus LPS and dexamethasone: 11.6 ± 7.7 pg/ml, p < 0.05); non-severe asthmatics (183 ± 122 versus 21.4 ± 22 pg/ml, p < 0.05) and severe asthmatics (230 ± 102 versus 60 ± 32 pg/ml, p < 0.01).
Negative_regulation (observed) of Gene_expression (subjects) of LPS associated with occupational lung diseases and dexamethasone
16) Confidence 0.08 Published 2010 Journal Respir Res Section Body Doc Link PMC2894769 Disease Relevance 0.77 Pain Relevance 0.22
This unresponsiveness can be at least partially overcome by high LPS levels that exceed those encountered in the absence of clinical infection [79].
Negative_regulation (overcome) of Gene_expression (levels) of LPS associated with agonist and infection
17) Confidence 0.05 Published 2010 Journal Fibrogenesis Tissue Repair Section Body Doc Link PMC2984459 Disease Relevance 0.31 Pain Relevance 0.32
Five miRNAs consistently responded to LPS infusion, four of which were downregulated (miR-146b, miR-150, miR-342, and let-7g) and one of which was upregulated (miR-143) [27].
Negative_regulation (downregulated) of Gene_expression (infusion) of LPS
18) Confidence 0.03 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2756627 Disease Relevance 0.94 Pain Relevance 0
In conclusion, our results indicate that repeated administration of LPS at the lung segmental level in sheep results in the development of mild mononuclear alveolitis and downregulated activation of TGF-?
Negative_regulation (repeated) of Gene_expression (administration) of LPS in lung
19) Confidence 0.02 Published 2006 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2706618 Disease Relevance 0.18 Pain Relevance 0.09
M) suppressed the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) as well as the production of nitric oxide (NO) in LPS-stimulated RAW 264.7 cells and astrocytes.
Negative_regulation (suppressed) of Gene_expression (production) of LPS in astrocytes
20) Confidence 0.02 Published 2007 Journal Mediators of Inflammation Section Abstract Doc Link PMC1874678 Disease Relevance 0.19 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox